SGCB and chronic thromboembolic pulmonary hypertension: The remaining five patients with CTEPH did not undergo an intervention (two did not agree, three were not eligible) and were receiving oral pulmonary vasodilators at follow-up (PDE5i: N = 2, sGC stimulator: N = 3), which took place at an average of 26 months (min–max: 4–47 months) after the first measurement.